Results 71 to 80 of about 7,402 (202)

Major revision version 13.0 of the European AIDS Clinical Society guidelines 2025

HIV Medicine, Volume 27, Issue 1, Page 18-32, January 2026.
Abstract Background The European AIDS Clinical Society (EACS) guidelines were revised for the 21st time in 2025, with updates covering all aspects of HIV care. Key Points of the Guidelines Update The structure of the guidelines has been reorganized into two parts: Part I focuses on the management and prevention of HIV and related infections, and Part ...
Juan Ambrosioni, Laura I. Levi, Jasmini Alagaratnam, Abiu Sempere, Andrea Mastrangelo, Paolo Paioni, Cristina Mussini, Catia Marzolini, Susanne Dam Nielsen, Charles Béguelin, Steven Welch, Anna Koval, Luis Mendao, Alasdair Bamford, Alexandra Calmy, Giovanni Guaraldi, Cristiana Oprea, Esteban Martínez, Jürgen K. Rockstroh, The EACS Governing Board   +19 more
wiley   +1 more source

Iatrogenic Adrenal Insufficiency Secondary to Combination Therapy with Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine and Interlaminar Triamcinolone Injection in an AIDS Patient

Journal of the International Association of Providers of AIDS Care, 2017
We report the first identified case of suspected iatrogenic adrenal insufficiency after an interlaminar injection of triamcinolone acetonide while on concomitant Stribild (elvitegravir 150 mg/cobicistat 150 mg/tenofovir disoproxil fumarate 300 mg ...
Chanie Wassner PharmD, BCCCP, Sutapa Maiti MD, Kurt Kodroff MD, MMM, Henry Cohen MS, PharmD, FCCM, BCPP, BCGP   +3 more
doaj   +1 more source

Presentations Due to Priapism in an Urban Hospital in Switzerland

Emergency Medicine International, Volume 2026, Issue 1, 2026.
Objective Priapism, a persisting erection not associated with sexual stimulation, can be ischaemic, with the risk of permanent erectile dysfunction, or nonischaemic. Drugs—e.g., injection therapies for erectile dysfunction, as well as neuroleptics, antidepressants and various other medicines—can also cause priapism.
Julian Dionigi Uhl, Lukas Koneval, Laila Schneidewind, Manuel Haschke, Aristomenis Exadaktylos, Evangelia Liakoni, Shashank Kaushik   +6 more
wiley   +1 more source

Comparable real‐world effectiveness between switches to cabotegravir + rilpivirine long‐acting or modern daily oral regimens in the United States: an OPERA cohort study

Journal of the International AIDS Society, Volume 28, Issue 12, December 2025.
Abstract Introduction Cabotegravir + rilpivirine long‐acting (CAB+RPV LA) injectable was approved in the United States in 2021 for HIV‐1 treatment in virologically suppressed (viral load [VL] <50 copies/mI individuals. In clinical trials, CAB+RPV LA was non‐inferior to oral antiretroviral therapy (ART) regimens in virologically suppressed individuals ...
Ricky K. Hsu, Michael G. Sension, Jennifer S. Fusco, Laurence Brunet, Quateka Cochran, Brooke Levis, Gayathri Sridhar, Vani Vannappagari, Jean Van Wyk, Michael B. Wohlfeiler, Gregory P. Fusco   +10 more
wiley   +1 more source

Clinical effectiveness of dolutegravir in the treatment of HIV/AIDS [PDF]

, 2015
Huda Taha,1 Archik Das,2 Satyajit Das1,3 1Integrated Sexual Health Service Coventry and Warwickshire Partnership NHS Trust, Coventry, 2School of Medicine, Birmingham University, Birmingham, 3Coventry University, Coventry, UK Abstract: Dolutegravir (DTG)
Das, A., Das, S., Taha, H.
core   +3 more sources

Minor Contribution of UGT1A1 Inhibition to Atazanavir‐Related Bilirubin Elevation Supported by Conservative PBPK Modeling and Clinical Data

Clinical Pharmacology &Therapeutics, Volume 119, Issue 3, Page 583-586, March 2026.
Jin Dong, Pradeep Sharma, Rasha Emara, Derek Cheung, Weifeng Tang, Diansong Zhou, David W. Boulton, Mats Någård, Miki S. Park   +8 more
wiley   +1 more source

Vitiligo Signature‐Based Drug Screening Identifies Fulvestrant as a Novel Immunotherapy Combination Strategy

Advanced Science, Volume 12, Issue 44, November 27, 2025.
A vitiligo‐derived gene signature predicts response to immune checkpoint blockade across multiple cancer cohorts, providing a framework for patient stratification. Building on this, Fulvestrant—a clinically approved estrogen receptor degrader—further enhances antitumor immunity by reprogramming tumor‐associated macrophages and promoting CD8⁺ T cell ...
Jie Zhu, Liting Huang, Suzhen Bi, WeiKaixin Kong, Wanting Feng, Yingjia Li, Zhengwei Xie, Peipei Shan, Sujie Zhu   +8 more
wiley   +1 more source

Artificial intelligence modelling of tyrosine kinase inhibitors at risk of malabsorption and bioavailability‐enhancing strategies

British Journal of Clinical Pharmacology, Volume 91, Issue 11, Page 3130-3140, November 2025.
Aims The study aims to predict and improve the absorption of tyrosine kinase inhibitors (TKIs) in patients with malabsorption issues, particularly those who have undergone bariatric surgery or are using proton‐pump inhibitors. The research involves 2 main components: the development of an artificial intelligence (AI) model to identify TKIs that are ...
Daan W. Huntjens, Olivier J. M. Béquignon, Stefanie D. Krens, Mark Löwenberg, Martine E. D. Chamuleau, Remco J. Molenaar, Anita M. G. Kramers, Marianne A. Kuijvenhoven, Imke H. Bartelink   +8 more
wiley   +1 more source

Early Diagnosis of Latent Tuberculosis Reactivation due to Drug Interaction between Cobicistat and Intranasal Fluticasone

Case Reports in Infectious Diseases, 2019
Background. Single-tablet antiretroviral therapy is currently the first-line choice for the treatment of HIV infection. Some therapeutic regimens contain the CYP3A4 inhibitor cobicistat, which can interact with drugs undergoing hepatic first-pass ...
Roberto Pineda-Reyes, Alena Klochko
doaj   +1 more source

Predicting OCT2/MATEs‐Mediated Drug Interactions in Healthy Volunteers and Patients with Chronic Kidney Disease: Insights from Extended Clearance Concept, Endogenous Biomarkers, and In Vitro Inhibition Studies (Perspectives from the International Transporter Consortium)

Clinical Pharmacology &Therapeutics, Volume 118, Issue 5, Page 994-1014, November 2025.
Organic cation transporter (OCT) 2 and multidrug and toxin extrusion (MATE) transporters play significant roles in the renal secretion of organic cations and drug–drug interactions (DDIs). Recent in vitro studies indicate that the Ki values for OCT2 exhibit substrate dependency and increase in potency with pre‐incubation.
Satoshi Asano, Aleksandra Galetin, Yoshiko Tomita, Kathleen M. Giacomini, Xiaoyan Chu, Xinning Yang, Toshimichi Nakamura, Hiroyuki Kusuhara, Yuichi Sugiyama   +8 more
wiley   +1 more source